Background/Objectives: Studies have suggested that smokers may have a lower risk of primary sclerosing cholangitis (PSC) although the results have been inconsistent. This systematic review and meta-analysis was conducted to summarize all available data to better characterize this association. Methods: A comprehensive literature review was conducted using Medline and Embase databases through January 2018 to identify all studies that compared the risk of PSC among current/former smokers versus nonsmokers. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird. Results: Seven case-control studies with 2,307,393 participants met the eligibility criteria and were included in the metaanalysis. The risk of PSC among current smokers and former smokers was significantly lower than nonsmokers with the pooled odds ratio of 0.31 (95% CI, 0.18-0.53) and 0.52 (95% CI, 0.44-0.61), respectively. The risk remained significantly lower among current smokers and former smokers compared with nonsmokers even when only patients with PSC without inflammatory bowel disease were included. Conclusions: A significantly decreased risk of PSC among current and former smokers was demonstrated in this study.
Introduction
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by progressive inflammation, destruction, and stricturing of the intrahepatic and extrahepatic bile ducts. 1 The 2011 reported incidence rate of PSC was approximately 0.8 per 100,000 person-years in North America and Europe. 2 The reported prevalence of PSC in the year 2000 from Olmsted County, Minnesota, USA, was 21 per 100,000 men and six per 100,000 women.
3 About 50% to 80% of patients with PSC also have concomitant ulcerative colitis (UC). 3, 4 The exact etiology of PSC is not known but several factors, including genetic predisposition, autoimmunity, and chronic entry of bacteria into the portal circulation, have been linked to its pathogenesis. 1, 5 Cigarette smoking is one of the leading preventable causes of mortality worldwide as smokers have a higher risk of developing cardiovascular diseases, lung cancer, and chronic obstructive pulmonary disease. 6, 7 However, interestingly, smoking is associated with a lower risk of UC [8] [9] [10] [11] and smoking cessation in patients with UC is associated with increased disease activity and hospitalization. 12 Smoking may also be associated with a lower risk of PSC as suggested by several epidemiologic studies, although the results from those studies were inconsistent. [13] [14] [15] [16] [17] [18] [19] This systematic review and meta-analysis was conducted to summarize all available evidence with the aim of better characterizing the relationship between smoking and PSC.
Methods

Information sources and search strategy
A systematic literature search was conducted using the Embase and Medline databases from inception to January 2018 to identify all original studies that reported the association between smoking and PSC. The systematic literature review was independently conducted by three investigators (KW, PP, and PU) using the search strategy that included the terms for ''primary sclerosing cholangitis,'' ''smoking,'' and ''cigarettes'' as described in online Supplementary Data 1. A manual search for additional potentially relevant studies using references from the included studies and selected review articles was also performed. No language limitation was applied. This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement, which is provided as online Supplementary Data 2. EndNote X7 (Clarivate Analytics, PA, USA) was used for study retrieval.
Selection criteria
Eligible studies must be case-control, cross-sectional or cohort studies that investigated the risk of PSC among current smokers and former smokers versus nonsmokers. They must provide the effect estimates (odds ratios (OR), relative risks, hazard ratios or standardized incidence ratio) with 95% confidence intervals (CI) or sufficient raw data to calculate the effect estimates. Inclusion was not restricted by study size. When more than one study using the same database/cohort was available, the study with the most comprehensive data/analyses was included.
Retrieved articles were independently reviewed for their eligibility by the same three investigators. Discrepancy was resolved by conference with all investigators. The Newcastle-Ottawa quality assessment scale was used to appraise the quality of study in three areas including the recruitment of cases and controls, the comparability between the two groups, and the ascertainment of the outcome of interest for cohort studies and the exposure of interest for case-control studies. 20 The modified Newcastle-Ottawa scale as described by Herzog et al. was used for cross-sectional studies. 21 Kappa statistics were used for evaluation of inter-rater agreement of the Newcastle-Ottawa scale.
Data abstraction
A structured data collection form was used to extract the following data from each study: title of the study, publication year, name of the first author, calendar year(s) when the study was conducted, country or countries where the study was conducted, number of participants, demographic data of participants, methods used to identify and verify diagnosis of PSC, as well as cigarette smoking status, adjusted effect estimates with 95% CI, and covariates that were adjusted in the multivariable analysis.
To ensure the accuracy, this data extraction process was independently performed by two investigators (KW and PP). Case record forms were cross-checked by the senior investigator (PU). Any data discrepancy was resolved by referring back to the original articles.
Statistical analysis
Data analysis was performed using the Review Manager 5.3 software from the Cochrane Collaboration (London, United Kingdom). Adjusted point estimates for the association between smoking status and PSC from each study were extracted and combined using the generic inverse variance method of DerSimonian and Laird, which assigned the weight of each study in the pooled analysis inversely to its variance. 22 Subgroup analysis on the association between smoking status and PSC without inflammatory bowel disease (IBD) was also performed using the same statistical technique.
In light of the high likelihood of between-study variance because of different study designs and ethnic backgrounds of the studied populations, the random-effect model was used. Cochran's Q test and I 2 statistic were used to determine the between-study heterogeneity. This I 2 statistic quantifies the proportion of total variation across studies that is due to true heterogeneity rather than chance. A value of I 2 of 0-25% represents insignificant heterogeneity, 26% to 50% represents low heterogeneity, 51% to 75% represents moderate heterogeneity, and more than 75% represents high heterogeneity. 23 Visualization by funnel plot was used to assess the presence of publication bias.
Results
A total of 408 potentially eligible articles were identified using our search strategy (143 articles from Medline and 265 articles from Embase). After the exclusion of 134 duplicated articles, 274 articles underwent title and abstract review. A total of 248 articles were excluded at this stage since they clearly did not fulfill the eligibility criteria based on type of article (they were case reports, correspondences, review articles, in vitro studies, animal studies or interventional studies), leaving 26 articles for full-text review. Nineteen of them were excluded after the full-length review as they did not report the outcome of interest. Finally, seven case-control studies [13] [14] [15] [16] [17] [18] [19] with 2,307,393 participants were included in the meta-analysis. The literature review and selection process are demonstrated in Figure 1 .
Literature review process
Potentially relevant articles identified from search of MEDLINE (n =143) and EMBASE database (n =265) and screened for retreival
Title and abstract reviewed of potentially relevant articles (n =274) 26 potentially relevant articles included for fulllength article review 7 articles were included in the meta-analysis.
19 articles were excluded since they did not report the outcome of interest.
248 articles were excluded based on title and abstract for clearly not fulfilling inclusion criteria on basis of type of article on basis of type of article, study design, population or outcome of interest Exclusion of 134 duplications Figure 1 . Literature review process. Table 1 . Main characteristics of the studies included in this meta-analysis.
Loftus et al. 16 van Erpecum et al. 19 Mitchell et al. 18 Andersen et al. The characteristics and quality assessment of the studies are presented in Table 1 . It should be noted that the inter-rater agreement for the quality assessment using the Newcastle-Ottawa scale was high with the kappa statistic of 0.68.
Risk of PSC among current smokers
Overall, the pooled analysis demonstrated a significantly decreased risk of PSC among current smokers compared with nonsmokers with a pooled OR of 0.31 (95% CI, 0.18-0.53). Statistical heterogeneity was high with an I 2 of 83% (Figure 2(a) ). Three studies 14, 16, 18 provided data on the association between subgroups of patients with PSC with and without IBD and smoking status. The pooled results of these three studies continued to show a significantly lower risk of PSC among current smokers compared with nonsmokers with a pooled OR of 0.29 (95% CI, 0.10-0.79; I 
Risk of PSC among former smokers
Overall, the pooled analysis demonstrated a decreased risk of PSC among former smokers compared with nonsmokers with a pooled OR of 0.52 (95% CI, 0.44-0.61). Statistical heterogeneity was not significant with an I 2 of 0% (Figure 3(a) ). Three studies 14, 16, 18 provided data on the association between subgroup of patients with PSC with and without IBD and smoking status. The pooled results of these three studies continued to show a significantly lower risk of PSC among former smokers compared with nonsmokers with a pooled OR of 0.60 (95% CI, 0.40-0.91; I 2 0%) and pooled OR of 0.49 (95% CI, 0.36-0.66; I 2 0%) for the PSC without IBD subgroup (Figure 3(b) ) and PSC with IBD subgroup (Figure 3(c) ), respectively. Figure 4 is the funnel plot used to assess the presence of publication bias in the meta-analysis of the risk of PSC among current smokers. The graph is asymmetric and suggests that publication bias in favor of protective results may have been present. Figure 5 is the funnel plot used to assess the presence of publication bias for the meta-analysis of the risk of PSC among former smokers. The graph is fairly symmetric and is not suggestive of publication bias.
Evaluation for publication bias
Discussion
The current study is the first systematic review and meta-analysis that summarizes all available data on the risk of PSC among current and former smokers. We found an approximately 70% and 50% decreased risk of PSC among current smokers and former smokers, respectively, compared with nonsmokers. The results may suggest the protective effect of cigarette smoking against development of PSC and the effect may attenuate after smoking cessation. However, the exact mechanisms behind this apparent protective effect are not known.
The association between smoking and a lower risk of UC is well known. [8] [9] [10] [11] Studies have suggested that cigarette smoking may decrease the risk of UC via alteration in intestinal permeability, immune response, colonic mucosal blood flow, and mucus production. 24, 25 Since UC is a strong predisposing factor for PSC, smokers may have a lower risk of PSC as they develop UC less often compared with nonsmokers. Nonetheless, UC is not the sole explanation for this negative association as subgroup analysis continued to show a significantly lower risk of PSC without IBD among current and former smokers compared with nonsmokers.
Although the pathogenesis of PSC is well understood, it is widely accepted that immunologically mediated bile duct injury is one of the key mechanisms 26 and bile duct epithelial cells in PSC are often targeted by T cells for immune-mediated attack. 27 Smoking has a wide range of effects on immunological function, including suppression of T cells and B-cell functions, 28, 29 which may lower the chance of cell-mediated autoimmunity and thus decrease the risk of PSC.
Although the literature review process of this study was robust and the included studies were of high quality, we acknowledge that this study had some limitations and the results should be interpreted with caution.
First, the statistical heterogeneity was moderate to high in the meta-analyses of risk of PSC among current smokers. Second, publication bias in favor of studies that showed a protective effect of smoking may have been present. Third, this is a meta-analysis of observation studies that can demonstrate only an association between the two conditions but could not establish causality. It is still possible the observed negative association is actually a function of confounders. In summary, this systematic review and meta-analysis demonstrated a significantly lower risk of PSC among current and former smokers.
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